bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | BIAF Stock NewsStockTitan·8 hours agoBIAF-4.51%BIAFW0.00%
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q SummaryTradingView·Aug 7 at 03:51 PMBIAF-4.51%BIAFW0.00%
bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 millionPUBT·Aug 7 at 07:02 AMBIAFW0.00%BIAF-4.51%
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung | BIAF Stock NewsStockTitan·Aug 6 at 11:00 PMBIAFW0.00%BIAF-4.51%
Index Additions, Acquisitions, and Delisting Risks: This Week's Moves in 10 Niche EquitiesGlobal Report·Aug 5 at 04:13 AMBAM+0.37%FLUT-0.39%
Big Tech's Infrastructure Spree and the Old Economy's ComebackGlobal Report·Aug 4 at 04:17 AMAKAM+1.06%VNET-0.20%
bioAffinity Technologies Faces Nasdaq Delisting Risk After NoticeTip Ranks·Jul 31 at 04:54 PMBIAFW0.00%BIAF-4.51%
bioAffinity Technologies faces Nasdaq delisting risk after shares trade below $1 bid-price minimumPUBT·Jul 31 at 04:15 PMBIAF-4.51%BIAFW0.00%
Surging Tanker Rates and Cooling Housing: Unbundling the Physical Value Chain in 2026Global Report·Jul 31 at 04:21 AMTOYO+1.86%NVR+0.52%
Navigating 2026 Macro Crosswinds: US Equities Grapple with Regulatory Spillovers and Inflationary PressuresGlobal Report·Jul 29 at 04:19 AMAOS-0.42%MICC+0.69%
